Antitumor activity of a novel antisense oligonucleotide against Akt1.
The AKT pathway is an important therapeutic target for cancer drug discovery as it functions as a main point for transducing extracellular and intracellular oncogenic signals. Moreover, alternations of the AKT pathway have been found in a wide range of cancers. In the present study, we found that an Akt1 antisense oligonucleotide (Akt1 AO) significantly downregulated the expression of AKT1 at both the mRNA and protein levels and inhibited cellular growth at nanomolar concentrations in various types of human cancer cells. Combined treatment of Akt1 AO with several cytotoxic drugs resulted in an additive growth inhibition of Caki-1 cells. The in vivo effectiveness of Akt1 AO was determined using two different xenograft nude mouse models. Akt1 AO (30 mg/kg, i.v. every 48 h) significantly inhibited the tumor growth of nude mouse subcutaneously implanted with U251 human glioblastoma cells after 27 days treatment. Akt1 AO (30 mg/kg, i.p continuously via osmotic pump) also significantly inhibited the tumor formation in nude mice implanted with luciferase-expressing MIA human pancreatic cancer cells (MIA-Luc) after 14 days of treatment. The luciferase signals from MIA-Luc cells were reduced or completely abolished after 2 weeks of treatment and the implanted tumors were barely detectable. Our findings suggest that Akt1 AO alone or in combination with other clinically approved anticancer agents should be further explored and progressed into clinical studies as a potential novel therapeutic agent.
Yoon
Heejeong
H
Rexahn Pharmaceuticals, Inc., 20271 Goldenrod Lane, Germantown, Maryland 20876, USA.
Kim
Deog Joong
DJ
Ahn
Eun Hyun
EH
Gellert
Ginelle C
GC
Shay
Jerry W
JW
Ahn
Chang-Ho
CH
Lee
Young Bok
YB
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D006367:HeLa Cells; D006801:Humans; D020128:Inhibitory Concentration 50; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; C494918:AKT1 protein, human; D051057:Proto-Oncogene Proteins c-akt
Semin Oncol. 1995 Aug;22(4 Suppl 11):3-10
7481842
Lancet Oncol. 2002 Nov;3(11):672-83
12424069
Cancer Res. 2006 Mar 15;66(6):3126-36
16540663
Cancer Res. 1997 Jun 15;57(12):2452-9
9192825
Adv Cancer Res. 2005;94:29-86
16095999
J Surg Res. 1999 Jan;81(1):101-7
9889067
Oncogene. 2005 Nov 14;24(50):7482-92
16288295
Proc Natl Acad Sci U S A. 1977 Jul;74(7):3065-7
197531
Cancer Res. 2001 Mar 1;61(5):1862-8
11280739
Nat Protoc. 2006;1(3):1112-6
17406391
Nat Rev Cancer. 2005 Jun;5(6):468-79
15905854
Proc Natl Acad Sci U S A. 1987 Jul;84(14):5034-7
3037531
Clin Sci (Lond). 1998 Sep;95(3):385-8
9730860
Neoplasia. 2001 Jul-Aug;3(4):278-86
11571628
Int J Mol Med. 1999 Jun;3(6):647-53
10341297
Cancer Res. 2007 Jul 1;67(13):6325-32
17616691
Biochem Pharmacol. 1998 Jan 1;55(1):53-64
9413930
Am J Pathol. 2001 Aug;159(2):431-7
11485901
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5
11572954
Surgery. 2005 Aug;138(2):360-7
16153448
J Cell Biochem. 2008 Jun 1;104(3):985-94
18275063
Cell Cycle. 2003 Jul-Aug;2(4):339-45
12851486
J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
2359136